Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 210 Recurrence 26 Neoplasms, Plasma Cell 15 Neoplasms 13 Immunoglobulin Light-chain Amyloidosis 13 Leukemia, Myeloid, Acute 9 Lymphoma, Non-Hodgkin 7 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6 Smoldering Multiple Myeloma 5 Lymphoma 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Neoplasm, Residual 4 Hematologic Neoplasms 4 Plasmacytoma 3 Paraproteinemias 3 Myelodysplastic Syndromes 3 Leukemia, Plasma Cell 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Hodgkin Disease 3 Hematologic Diseases 3 Carcinoma, Non-Small-Cell Lung 3 Amyloidosis 3 Waldenstrom Macroglobulinemia 2 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Plasmablastic Lymphoma 2 Lymphoma, Large B-Cell, Diffuse 2 Disease 2 Corneal Diseases 2 Blood Protein Disorders 2

Interventions

Nivolumab 5 Ipilimumab 3 relatlimab 1 daratumumab 1 Fluorouracil 1 Cisplatin 1 BMS-986115 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Various Advanced Cancer × daratumumab × Clear all

NCT02488759 2023-11-13

CheckMate358

Bristol-Myers Squibb

Phase 1/2 Completed

578 enrolled 19 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡